Abstract:Liquid biopsy enables emerging biomarkers detection, such as circulating tumor DNA (ctDNA), microRNAs (miRNAs), and exosomes, leading to real-time monitoring of cancer progression and therapy effectiveness. Important circulating miRNAs, serving as biomarkers, have been correlated to breast cancer (BC) metastasis and therapy efficiency. In particular, among the BC, the Triple negative BC (TNBC) is an aggressive and heterogeneous subtype, accounting for 40% of BC related mortality. Rapid detection of these miRNAs through non-invasive liquid biopsy can significantly enhance diagnosis and prognosis, thereby improving survival rates. Considering these emerging biomarkers within the framework of personalized medicine, affordable and portable devices could enable quicker monitoring for cancer patients, including those in remote areas. In this context, we have developed an enzyme-assisted electrochemical point-of-care (POC) test. The proposed miRNA detection system is boosted by the use of duplex-specific nuclease (DSN) as the recognition element of miRNA. The DSN enzyme exhibits high selectivity to discriminate DNA-RNA heteroduplexes triggering isothermal target recycling and signal enhancement. This capability is crucial for overcoming the limitations often associated with detecting trace amounts of miRNA in biofluids. In our study, the specific probe for the miRNA target was labelled with a redox mediator, methylene blue, to enable the detection of enzymatic products via electrochemical measurements on screen-printed electrode. Optimization studies have been performed to obtain the enzymatic reaction in terms of probe and enzyme concentration. A calibration graph was obtained for various target concentrations ranging from 0.1 pM to100 nM, and a detection limit down to the fM level was achieved. Specificity studies were performed with random miRNA targets, and finally the device was applied in spiked commercial serum samples. These promising results suggest potential for developing novel class of POC tests towards the realization of an all-in-one sustainable platform for liquid biopsy applications.

What problem does this paper attempt to address?

The paper aims to develop an enzyme-assisted electrochemical point-of-care (POC) testing method for detecting microRNA (miRNA) in liquid biopsy samples. The specific objectives are: 1. **Address the issues of traditional cancer monitoring methods**: Traditional tissue biopsy methods are invasive, may cause side effects, are costly, and time-consuming. Therefore, researchers are seeking non-invasive liquid biopsy techniques to overcome these issues. 2. **Improve early diagnosis and treatment outcomes for breast cancer, especially Triple-negative breast cancer (TNBC)**: TNBC is an aggressive and highly heterogeneous subtype of breast cancer, with a breast cancer-related mortality rate of up to 40%. Rapid detection of miRNA associated with TNBC can significantly improve diagnosis and prognosis, thereby increasing survival rates. 3. **Develop portable, low-cost point-of-care testing devices**: To achieve rapid monitoring of miRNA, the research team designed an electrochemical POC testing system based on Duplex-specific nuclease (DSN). This system can achieve sensitive detection of very low concentrations of miRNA by recognizing specific miRNA sequences and triggering signal amplification. 4. **Validate system performance**: The study evaluated the sensitivity, selectivity, and potential application in real samples of the system. The results showed that the system could achieve a detection limit as low as 30 femtomolar (fM) and successfully detected different concentration levels of miRNA in commercial serum samples. 5. **Future applications outlook**: This research lays the foundation for developing a sustainable integrated platform, which is expected to promote the application of liquid biopsy and provide powerful tools for personalized medicine for breast cancer and other cancer patients.

Enzyme-assisted electrochemical point-of-care test for miRNA detection towards liquid biopsy application